A practical reference on nuclear receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
=== Contestants === 1st-Hollie Fraser, Bakery Owner from Port Moody, British Columbia 2/3rd-James Cox, Bakery Owner and Pastry Chef from Chicago, Illinois 2/3rd-Ryan McCord, Pastry Chef from Nashville, Tennessee 4th-Stacy Day, Pastry Chef from Nashville, Tennessee 5th-Christa Aylward, Bakery Owner from Dublin, Ohio 6th-Mandi Del Toro, Home Baker from San Antonio, Texas 7/8th-Shefali Patel, Home Baker from Coppell, Texas 7/8th-Dan Pivovar, Pastry Chef from Onalaska, Wisconsin 9th-Adesuwa Elaiho, Bakery Owner from San Antonio, Texas 10th-Phoebe Martinson, Bakery Owner from Olympia, Washington 11th-Chad Conklin, Culinary Instructor from Dayton, Ohio 12th-Mike Yu, Restaurant Owner from Napa, California
=== Resistance === Three mechanisms of resistance to chloramphenicol are known: reduced membrane permeability, mutation of the 50S ribosomal subunit, and elaboration of chloramphenicol acetyltransferase. It is easy to select for reduced membrane permeability to chloramphenicol in vitro by serial passage of bacteria, and this is the most common mechanism of low-level chloramphenicol resistance. High-level resistance is conferred by the cat-gene; this gene codes for an enzyme called chloramphenicol acetyltransferase, which inactivates chloramphenicol by covalently linking one or two acetyl groups, derived from acetyl-S-coenzyme A, to the hydroxyl groups on the chloramphenicol molecule. The acetylation prevents chloramphenicol from binding to the ribosome. Resistance-conferring mutations of the 50S ribosomal subunit are rare. Chloramphenicol resistance may be carried on a plasmid that also codes for resistance to other drugs. One example is the ACCoT plasmid (A=ampicillin, C=chloramphenicol, Co=co-trimoxazole, T=tetracycline), which mediates multiple drug resistance in typhoid (also called R factors). As of 2014 some Enterococcus faecium and Pseudomonas aeruginosa strains are resistant to chloramphenicol. Some Veillonella spp. and Staphylococcus capitis strains have also developed resistance to chloramphenicol to varying degrees. Some other resistance genes beyond cat are known, such as chloramphenicol hydrolase, and chloramphenicol phosphotransferase.
(p) .signature (UNIX shell/Internet standard file name) (a/i) Special Interest Group (a/i) Strasbourg Illkirch-Graffenstaden Basket (French basketball club) SIGCAT – (a) Special Interest Group for CD-ROM Applications and Technology SIGINT – (p) Signals Intelligence SIGMET – (p) Significant Meteorological Information SIIT (i) Saskatchewan Indian Institute of Technologies (Canadian university) Sirindhorn International Institute of Technology (Thai university) Stateless IP/ICMP Translation algorithm SIMAC – (a) Semantic Interaction with Music Audio Contents SIMLAS – (p) Soldier Integrated Multipurpose Laser System SIMM – (a) Single In-line Memory Module SIMNET – (p) SIMulator NETwork, later SIMulation NETwork SIMNET-D - (p) SIMNET-Developmental SIMP – (a) Strongly Interacting Massive Particle SIMPLE (a) Satellite Interactive Multimedia Platform for Low-cost Earth stations (p) Savings Incentive Match Plan for Employees (as used in SIMPLE IRA) (a) Standard Interface for Multiple Platform Link Evaluation (NATO STANAG 5602) sin – (s) Sinhala language (ISO 639-2 code) SIN – (a) Social insurance number (Canada) SINCGARS – (p) SINgle Channel Ground and Airborne Radio System SIP (i) Session Initiation Protocol State Implementation Plan System Improvement Program Systematic investment plan SIPP – (a) Self-Invested Personal Pension Siri – (a) Speech Interpretation and Recognition Interface (Apple iOS software) SIRI – (a) Service Interface for Real Time Information SIRS — (a) Systemic inflammatory response syndrome SiS – (i) Silicon Integrated Systems SIS – (i) UK Secret Intelligence Service (also known as MI6) SISO (a) Simulation Interoperability Standards Organization Society of Independent Show Organizers SIW – (i) Simulation Interoperability Workshop SIYSS – (i) Stockholm International Youth Science Seminar
== Function == This gene is a member of the NAD(P)H dehydrogenase (quinone) family and encodes a cytoplasmic 2-electron reductase. This FAD-binding protein forms homodimers and reduces quinones to hydroquinones. This enzyme facilitates the two electron reduction of quinone to hydroquinone. NQO1-mediated two electron reduction of quinone to hydroquinone thereby indirectly prevents the one electron reduction of quinone to the semiquinone free radical. The ubiquitin-independent p53 degradation pathway is regulated by NQO1. NQO1 stabilizes p53, protecting it from degradation. Individuals with decreased NQO1 expression/activity have reduced p53 stability, which may lead to resistance to drugs such as chemotherapeutics.
Sources: en.wikipedia.org
Low-level waste (LLW) is generated from hospitals and industry, as well as the nuclear fuel cycle. Low-level wastes include paper, rags, tools, clothing, filters, and other materials which contain small amounts of mostly short-lived radioactivity. Materials that originate from any region of an active area are commonly designated as LLW as a precautionary measure even if there is only a remote possibility of being contaminated with radioactive materials. Such LLW typically exhibits no higher radioactivity than one would expect from the same material disposed of in a non-active area, such as a normal office block. Example LLW includes wiping rags, mops, medical tubes, laboratory animal carcasses, and more. LLW makes up 94% of all radioactive waste volume in the UK. Most of it is disposed of in Cumbria, first in landfill style trenches, and now using grouted metal containers that are stacked in concrete vaults. A new site in the north of Scotland is the Dounreay site which is prepared to withstand a 4m tsunami.[1] Some high-activity LLW requires shielding during handling and transport but most LLW is suitable for shallow land burial. To reduce its volume, it is often compacted or incinerated before disposal. Low-level waste is divided into four classes: class A, class B, class C, and Greater Than Class C (GTCC).
== GLP-1, GIP, and glucagon receptor triple agonists == Following the discovery of GLP-1/GIP and GLP-1/glucagon dual agonists, it was hoped that a triple agonist would provide additive or synergistic metabolic benefits. A clinical trial of the triple agonist retatrutide found an average 24.2% weight reduction in the highest dosage group after 24 weeks. Another clinical trial of triple agonist UBT-251 also found an average weight reduction of 19.7% after 24 weeks.
Glucose + 2 NAD+ + 2 Pi + 2 ADP → 2 pyruvate + 2 NADH + 2 ATP + 2 H+ + 2 H2O + energy Starting with glucose, 1 ATP is used to donate a phosphate to glucose to produce glucose 6-phosphate. Glycogen can be converted into glucose 6-phosphate as well with the help of glycogen phosphorylase. During energy metabolism, glucose 6-phosphate becomes fructose 6-phosphate. An additional ATP is used to phosphorylate fructose 6-phosphate into fructose 1,6-bisphosphate by the help of phosphofructokinase. Fructose 1,6-biphosphate then splits into two phosphorylated molecules with three carbon chains which later degrades into pyruvate.
In geometry, Barrow's inequality is an inequality relating the distances between an arbitrary point within a triangle, the vertices of the triangle, and certain points on the sides of the triangle. It is named after David Francis Barrow.
=== Mechanism of action === Isoliquiritigenin has been found to be a potent (65 times higher affinity than diazepam) GABA-A benzodiazepine receptor positive allosteric modulator with hypnotic effects in mice. It competitively inhibits human monoamine oxidase enzymes and interacts with dopamine and vasopressin receptors.
Sources: en.wikipedia.org
=== Spectrophotometric === In spectrophotometric assays, you follow the course of the reaction by measuring a change in how much light the assay solution absorbs. If this light is in the visible region you can actually see a change in the color of the assay, and these are called colorimetric assays. The MTT assay, a redox assay using a tetrazolium dye as substrate is an example of a colorimetric assay. UV light is often used, since the common coenzymes NADH and NADPH absorb UV light in their reduced forms, but do not in their oxidized forms. An oxidoreductase using NADH as a substrate could therefore be assayed by following the decrease in UV absorbance at a wavelength of 340 nm as it consumes the coenzyme. Direct versus coupled assays
== Drug overdose and management == Cardiovascular agents generally have narrow therapeutic indices, implying that small differences in dose or blood concentration may give rise to adverse drug reactions. Serious acute toxicity may result from accidental, intentional or iatrogenic overdose. Therefore, patients need to be aware of any unusual and serious side effects. Seek immediate medical attention if a drug overdose is suspected.
A quadcopter strike from Afghanistan on a cricket ground in Bajaur district, injured three civilians. On 2 May, Counter Terrorism Department claimed to have captured 21 suspected militants including those belonging to TTP in operations throughout Punjab. Pakistan claimed that 52 civilians had been killed in attacks from Afghanistan since the resumption of hostilities after the temporary ceasefire on Eid-ul-Fitr. On 3 May, a policeman was killed by militants in Lakki Marwat. A TTP commander was killed in an operation in Dera Ismail Khan. On 4 May, Pakistan reportedly launched an attack which resulted in the deaths of three civilians and the destruction of multiple schools, mosques, and a health center in Afghanistan. Pakistan disputed the claims. On the same day, a suicide attack foiled by security forces at a border checkpoint in Khyber Pakhtunkhwa resulted in a single casualty, seven civilians were also wounded. Afghan Taliban deployed hundreds of fighters and dozens of military vehicles to Spin Boldak, Shorabak and Registan districts along the Pakistan border in Kunar Province from other areas. On 6 May 2026, in Hangu district, security forces launched an operation after militants captured a police checkpost, a school and Shinwari Fort. On 7 May 2026, three children were killed and 10 civilians were wounded in a cylinder bombing by TTP and mortar attacks by Afghan Taliban in South Waziristan.
==== Record GDP growth ==== At the end of 2023, Brazil once again became one of the ten largest economies in the world, according to the IMF, the country had dropped out of the ranking between 2019 and 2022, when it fell to 13th place. Also at the end of 2023, the Brazilian trade balance marked the largest surplus in its history, with 98 billion dollars, a significant jump in relation to the 2022 surplus, of 61 billion dollars, which was the previous record. This increase was sustained by the 1.7% increase in exports and the 11.7% drop in imports, resulting from the 8.8% decline in the price of imported items, such as fertilizers, whose price decreased by 44.9% in comparison with 2022. The current account showed a deficit of 28 billion dollars in 2023 and direct investment in the country totaled 62 billion dollars. Released on 1 March 2024, Brazil's GDP grew 2.9% in the first year of the Lula government. The increase was driven especially by the super harvest in the agricultural sector, the recovery of the services sector and the job market, the maintenance of social spending, and the expansion of fiscal space opened by the New Fiscal Framework; growth surpassed the first year of the Bolsonaro, Temer, Dilma 2, Lula 1 and FHC 2 governments, being lower only than the first year of the Dilma 1, Lula 2 and FHC 1 governments.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.